Mirtazapine

Generic Name
Mirtazapine
Brand Names
Remeron
Drug Type
Small Molecule
Chemical Formula
C17H19N3
CAS Number
85650-52-8
Unique Ingredient Identifier
A051Q2099Q
Background

Mirtazapine is a tetracyclic piperazino-azepine antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder. The effects of this drug may be observed as early ...

Indication

This drug is indicated for the treatment of major depressive disorder and its associated symptoms.
...

Associated Conditions
Cancer Pain, Depression, Fibromyalgia, Generalized Anxiety Disorder, Hot Flashes, Insomnia, Major Depressive Disorder (MDD), Obsessive Compulsive Disorder (OCD), Panic Disorder, Persistent Depressive Disorder (Dysthymia), Post Operative Nausea and Vomiting (PONV), Poststroke depression, Sleep disorders and disturbances, Substance Abuse Disorders, Tension Headache
Associated Therapies
-
Clinical Trials
Related News

A Diagnosis and Treatment Optimization Study of Depression Based on the Neurological Mechanism of Reward System

First Posted Date
2017-05-11
Last Posted Date
2019-12-13
Lead Sponsor
Peking University
Target Recruit Count
120
Registration Number
NCT03148522
Locations
🇨🇳

Yun-Ai SU, Beijing, Beijing, China

Study of Mirtazapine for Agitation in Dementia

Phase 3
Completed
Conditions
Dementia
Interventions
Drug: Mirtazapine
Other: Placebo
First Posted Date
2017-01-25
Last Posted Date
2021-04-19
Lead Sponsor
University of Sussex
Target Recruit Count
207
Registration Number
NCT03031184
Locations
🇬🇧

Sube Banerjee, Brighton, Sussex, United Kingdom

Longitudinal Comparative Effectiveness of Bipolar Disorder Therapies

Terminated
Conditions
Bipolar Disorder
First Posted Date
2016-09-08
Last Posted Date
2024-03-12
Lead Sponsor
University of New Mexico
Target Recruit Count
1037352
Registration Number
NCT02893371
Locations
🇺🇸

Christophe G Lambert, Albuquerque, New Mexico, United States

A Policy Relevant US Trauma Care System Pragmatic Trial for PTSD and Comorbidity

First Posted Date
2016-01-14
Last Posted Date
2021-07-02
Lead Sponsor
University of Washington
Target Recruit Count
635
Registration Number
NCT02655354
Locations
🇺🇸

Jacobi Medical Center, Bronx, New York, United States

🇺🇸

University of Rochester, Rochester, New York, United States

🇺🇸

Honor Health, Scottsdale, Arizona, United States

and more 21 locations

Efficacy and Safety Analyses of Mirtazapine in NSCLC Patients With Depression

First Posted Date
2016-01-08
Last Posted Date
2016-01-08
Lead Sponsor
Sun Yat-sen University
Target Recruit Count
236
Registration Number
NCT02650544
Locations
🇨🇳

Cancer Center of Sun-Yat Sen University (CCSYSU), GuangZhou, Guangdong, China

Treatment of Young Adults With Comorbid AUD/MDD: A Pilot Medication Trial

First Posted Date
2016-01-05
Last Posted Date
2017-04-27
Lead Sponsor
University of Pittsburgh
Target Recruit Count
11
Registration Number
NCT02646449
Locations
🇺🇸

Western Psychiatric Institute and Clinic, Pittsburgh, Pennsylvania, United States

Mirtazapine as a Treatment for Co-Occurring Opioid and ATS Dependence in Malaysia

First Posted Date
2015-09-04
Last Posted Date
2015-09-04
Lead Sponsor
Universiti Sains Malaysia
Target Recruit Count
80
Registration Number
NCT02541526
Locations
🇲🇾

University Science Malaysia, Kota bharu, Kelantan, Malaysia

Pharmacovigilance in Gerontopsychiatric Patients

Phase 3
Terminated
Conditions
Dementia
Depression
Schizophrenia
Psychosomatic Disorders
Anxiety Disorders
Interventions
Drug: Phenobarbital
Drug: Phenytoin
Drug: Carbamazepine
Drug: Oxcarbazepine
Drug: Valproic Acid
Drug: Lamotrigine
Drug: Topiramate
Drug: Gabapentin
Drug: Levetiracetam
Drug: Pregabalin
Drug: Lacosamide
Drug: Clonazepam
Drug: Biperiden
Drug: Levomepromazine
Drug: Fluphenazine
Drug: Perphenazine
Drug: Perazine
Drug: Thioridazine
Drug: Haloperidol
Drug: Melperone
Drug: Pipamperone
Drug: Bromperidol
Drug: Benperidol
Drug: Sertindole
Drug: Ziprasidone
Drug: Flupentixol
Drug: Chlorprothixene
Drug: Zuclopenthixol
Drug: Fluspirilene
Drug: Pimozide
Drug: Clozapine
Drug: Olanzapine
Drug: Quetiapine
Drug: Sulpiride
Drug: Tiapride
Drug: Amisulpride
Drug: Prothipendyl
Drug: Risperidone
Drug: Aripiprazole
Drug: Paliperidone
Drug: Diazepam
Drug: Oxazepam
Drug: Lorazepam
Drug: Bromazepam
Drug: Clobazam
Drug: Alprazolam
Drug: Hydroxyzine
Drug: Buspirone
Drug: Chloral Hydrate
Drug: Flurazepam
Drug: Nitrazepam
Drug: Triazolam
Drug: Lormetazepam
Drug: Temazepam
Drug: Midazolam
Drug: Brotizolam
Drug: Zopiclone
Drug: Zolpidem
Drug: Zaleplon
Drug: Melatonin
Drug: Clomethiazole
Drug: Diphenhydramine
Drug: Promethazine
Drug: Imipramine
Drug: Clomipramine
Drug: Opipramol
Drug: Trimipramine
Drug: Amitriptyline
Drug: Nortriptyline
Drug: Doxepin
Drug: Maprotiline
Drug: Amitriptyline oxide
Drug: Fluoxetine
Drug: Citalopram
Drug: Paroxetine
Drug: Sertraline
Drug: Fluvoxamine
Drug: Escitalopram
Drug: Tranylcypromine
Drug: Moclobemide
Drug: Mianserin
Drug: Trazodone
Drug: Mirtazapine
Drug: Bupropion
Drug: Venlafaxine
Drug: Reboxetine
Drug: Duloxetine
Drug: Agomelatine
Drug: Pyritinol
Drug: Piracetam
Drug: Donepezil
Drug: Rivastigmine
Drug: Galantamine
Drug: Memantine
Drug: Nicergoline
Drug: Acamprosate
Drug: Lithium
First Posted Date
2015-03-02
Last Posted Date
2018-02-28
Lead Sponsor
Hannover Medical School
Target Recruit Count
407
Registration Number
NCT02374567
Locations
🇩🇪

Bezirkskrankenhaus Augsburg, Augsburg, Germany

🇩🇪

Krankenhaus Hedwigshöhe, Berlin, Germany

🇩🇪

Hannover Medical School, Hannover, Germany

and more 2 locations

Adding Mirtazapine to Dexamethasone and Aprepitant for Delayed Emesis

Phase 3
Completed
Conditions
Breast Cancer
Interventions
Drug: Aprepitant
Drug: Mirtazapine
First Posted Date
2015-01-13
Last Posted Date
2022-04-20
Lead Sponsor
Fudan University
Target Recruit Count
212
Registration Number
NCT02336750
Locations
🇨🇳

Fudan University Cancer Hospital, Shanghai, China

Study to Assess the Effects of Esketamine on Safety of On-road Driving in Healthy Participants

First Posted Date
2014-08-28
Last Posted Date
2014-12-30
Lead Sponsor
Janssen Research & Development, LLC
Target Recruit Count
26
Registration Number
NCT02228239
© Copyright 2024. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy